| scholarly article | Q13442814 |
| P50 | author | Katherine L Nathanson | Q37369859 |
| George Coukos | Q46574285 | ||
| Heini Lassus | Q50742234 | ||
| Dionyssios Katsaros | Q114421372 | ||
| P2093 | author name string | Lin Zhang | |
| Yan Wang | |||
| Andrew K Godwin | |||
| Jia Huang | |||
| Barbara L Weber | |||
| Joel Greshock | |||
| Joseph R Testa | |||
| Phyllis A Gimotty | |||
| Ralf Butzow | |||
| Theresa A Colligon | |||
| Renee Ward | |||
| Yan Degenhardt | |||
| P2860 | cites work | 1-Mb resolution array-based comparative genomic hybridization using a BAC clone set optimized for cancer gene analysis | Q24629750 |
| Comprehensive genomic characterization defines human glioblastoma genes and core pathways | Q24656128 | ||
| Identification of IGF2 signaling through phosphoinositide-3-kinase regulatory subunit 3 as a growth-promoting axis in glioblastoma | Q24670758 | ||
| High frequency of mutations of the PIK3CA gene in human cancers | Q28131776 | ||
| Cancer genes and the pathways they control | Q28275089 | ||
| Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis | Q28288381 | ||
| Reduced expression of the murine p85alpha subunit of phosphoinositide 3-kinase improves insulin signaling and ameliorates diabetes | Q28344700 | ||
| The phosphatidylinositol 3-Kinase AKT pathway in human cancer | Q29547860 | ||
| Circular binary segmentation for the analysis of array-based DNA copy number data | Q29615406 | ||
| Tissue microarrays for high-throughput molecular profiling of tumor specimens | Q29618675 | ||
| On the road to cancer: aneuploidy and the mitotic checkpoint | Q29619455 | ||
| Identification of candidate growth promoting genes in ovarian cancer through integrated copy number and expression analysis | Q33553289 | ||
| The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy | Q34437249 | ||
| Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer | Q34652960 | ||
| Integrated genomic and transcriptional profiling identifies chromosomal loci with altered gene expression in cervical cancer | Q34794711 | ||
| Role of Jun and Jun kinase in resistance of cancer cells to therapy | Q35177662 | ||
| Oncogenic pathways implicated in ovarian epithelial cancer | Q35213223 | ||
| Targeting PI3K-AKT pathway for cancer therapy | Q35648847 | ||
| p38 MAP kinase: a convergence point in cancer therapy | Q35753071 | ||
| Targeting the mitogen-activated protein kinase cascade to treat cancer | Q35968411 | ||
| Wnt/beta-catenin signaling pathway as a novel cancer drug target | Q35971885 | ||
| Origins and molecular pathology of ovarian cancer | Q36068263 | ||
| Role of transforming growth factor Beta in human cancer | Q36073421 | ||
| Array comparative genomic hybridization and its applications in cancer | Q36141621 | ||
| Promoting apoptosis as a strategy for cancer drug discovery | Q36292878 | ||
| Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance | Q37036297 | ||
| Cancer cell lines as genetic models of their parent histology: analyses based on array comparative genomic hybridization | Q40144602 | ||
| PI3K: A rational target for ovarian cancer therapy? | Q44944249 | ||
| Array-based comparative genomic hybridization for the differential diagnosis of renal cell cancer. | Q46876220 | ||
| RNA interference-mediated silencing of the phosphatidylinositol 3-kinase catalytic subunit attenuates growth of human ovarian cancer cells in vitroand in vivo | Q47806450 | ||
| The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. | Q52832711 | ||
| Chromosome 5 imbalance mapping in breast tumors from BRCA1 and BRCA2 mutation carriers and sporadic breast tumors. | Q54611493 | ||
| Distinct subtypes of serous ovarian carcinoma identified by p53 determination | Q79366828 | ||
| Integrative genomic analysis of phosphatidylinositol 3'-kinase family identifies PIK3R3 as a potential therapeutic target in epithelial ovarian cancer | Q81310317 | ||
| Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms | Q83833643 | ||
| P433 | issue | 8 | |
| P921 | main subject | ovarian cancer | Q172341 |
| patient | Q181600 | ||
| P304 | page(s) | 606-618 | |
| P577 | publication date | 2011-05-11 | |
| P1433 | published in | Genes, Chromosomes and Cancer | Q5532697 |
| P1476 | title | Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome | |
| P478 | volume | 50 |
| Q92307108 | A newly synthesized platinum-based compound (PBC-II) increases chemosensitivity of HeLa ovarian cancer cells via inhibition of autophagy |
| Q50041754 | ABT-737 and pictilisib synergistically enhance pitavastatin-induced apoptosis in ovarian cancer cells |
| Q64054222 | Akt inhibitor SC66 promotes cell sensitivity to cisplatin in chemoresistant ovarian cancer cells through inhibition of COL11A1 expression |
| Q93032395 | Alteration of tumor associated neutrophils by PIK3CA expression in endometrial carcinoma from TCGA data |
| Q58775646 | Anticancer Activity of Metformin, an Antidiabetic Drug, Against Ovarian Cancer Cells Involves Inhibition of Cysteine-Rich 61 (Cyr61)/Akt/Mammalian Target of Rapamycin (mTOR) Signaling Pathway |
| Q37406889 | Beside P53 and PTEN: Identification of molecular alterations of the RAS/MAPK and PI3K/AKT signaling pathways in high-grade serous ovarian carcinomas to determine potential novel therapeutic targets |
| Q90478814 | Comparing PI3K/Akt Inhibitors Used in Ovarian Cancer Treatment |
| Q34189765 | Differential analysis of ovarian and endometrial cancers identifies a methylator phenotype |
| Q60920503 | Differing Roles of Hyaluronan Molecular Weight on Cancer Cell Behavior and Chemotherapy Resistance |
| Q37256292 | Effects of Kras activation and Pten deletion alone or in combination on MUC1 biology and epithelial-to-mesenchymal transition in ovarian cancer |
| Q24621116 | Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts |
| Q34022694 | Estrogen signaling crosstalk: Implications for endocrine resistance in ovarian cancer |
| Q90706190 | Evaluation of core serous epithelial ovarian cancer genes as potential prognostic markers and indicators of the underlying molecular mechanisms using an integrated bioinformatics analysis |
| Q37497233 | Frequent copy number variations of PI3K/AKT pathway and aberrant protein expressions of PI3K subunits are associated with inferior survival in diffuse large B cell lymphoma |
| Q64111448 | High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints |
| Q92517890 | In Preclinical Model of Ovarian Cancer, the SGK1 Inhibitor SI113 Counteracts the Development of Paclitaxel Resistance and Restores Drug Sensitivity |
| Q55396493 | Integrated multi-omics data analysis identifying novel drug sensitivity-associated molecular targets of hepatocellular carcinoma cells. |
| Q89622527 | Long Non-coding RNAs Involved in Resistance to Chemotherapy in Ovarian Cancer |
| Q33566765 | Loss of PFKFB4 induces cell death in mitotically arrested ovarian cancer cells |
| Q35872796 | Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy |
| Q35402720 | Minocycline attenuates hypoxia-inducible factor-1α expression correlated with modulation of p53 and AKT/mTOR/p70S6K/4E-BP1 pathway in ovarian cancer: in vitro and in vivo studies |
| Q64981749 | Molecular subtyping of cancer and nomination of kinase candidates for inhibition with phosphoproteomics: Reanalysis of CPTAC ovarian cancer. |
| Q48124146 | Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells |
| Q37159783 | Overexpression of GAB2 in ovarian cancer cells promotes tumor growth and angiogenesis by upregulating chemokine expression. |
| Q91714664 | PI3K-AKT-mTOR and NFκB Pathways in Ovarian Cancer: Implications for Targeted Therapeutics |
| Q43300329 | PI3K/AKT/mTOR Pathway in Ovarian Cancer Treatment: Are We on the Right Track? |
| Q37420213 | Pathway modulations and epigenetic alterations in ovarian tumorbiogenesis |
| Q34371477 | REDD1 and p-AKT over-expression may predict poor prognosis in ovarian cancer |
| Q30576727 | Reducing confounding and suppression effects in TCGA data: an integrated analysis of chemotherapy response in ovarian cancer |
| Q64105994 | Rosmarinic Acid Analogue-11 Induces Apoptosis of Human Gastric Cancer SGC-7901 Cells via the Epidermal Growth Factor Receptor (EGFR)/Akt/Nuclear Factor kappa B (NF-κB) Pathway |
| Q89537567 | SPOCD1 accelerates ovarian cancer progression and inhibits cell apoptosis via the PI3K/AKT pathway |
| Q38605020 | Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response. |
| Q37214329 | Targeting EGFR and PI3K pathways in ovarian cancer |
| Q37180279 | The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28-Costimulated T Cells Prepared for Adoptive Therapy. |
| Q26851852 | The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges |
| Q36242802 | The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer. |
| Q37488549 | The diarylheptanoid hirsutenone sensitizes chemoresistant ovarian cancer cells to cisplatin via modulation of apoptosis-inducing factor and X-linked inhibitor of apoptosis. |
| Q36820568 | The importance of the PI3K/AKT/MTOR pathway in the progression of ovarian cancer |
| Q36851569 | The retinoic acid derivative, ABPN, inhibits pancreatic cancer through induction of Nrdp1 |
| Q26786826 | The role of reproductive hormones in epithelial ovarian carcinogenesis |
| Q33577824 | The role of the PTEN/PI3K/Akt pathway on prognosis in epithelial ovarian cancer: a meta-analysis |
| Q64232980 | UNBS5162 inhibits SKOV3 ovarian cancer cell proliferation by regulating the PI3K/AKT signalling pathway |
| Q92556126 | Wogonin Increases Cisplatin Sensitivity in Ovarian Cancer Cells Through Inhibition of the Phosphatidylinositol 3-Kinase (PI3K)/Akt Pathway |
Search more.